Share on StockTwits

Momenta Pharmaceuticals (NASDAQ:MNTA) President Craig A. Wheeler unloaded 1,768 shares of the stock on the open market in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $11.75, for a total value of $20,774.00. Following the completion of the transaction, the president now directly owns 372,286 shares in the company, valued at approximately $4,374,361. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) traded down 0.04% on Tuesday, hitting $11.78. 29,256 shares of the company’s stock traded hands. Momenta Pharmaceuticals has a one year low of $9.85 and a one year high of $19.90. The stock’s 50-day moving average is $11.31 and its 200-day moving average is $12.89. The company’s market cap is $606.5 million.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Thursday, July 31st. The company reported ($0.51) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.46) by $0.05. The company had revenue of $11.00 million for the quarter, compared to the consensus estimate of $11.22 million. During the same quarter last year, the company posted ($0.57) earnings per share. Momenta Pharmaceuticals’s revenue was up 151.1% compared to the same quarter last year. Analysts expect that Momenta Pharmaceuticals will post $-1.14 EPS for the current fiscal year.

MNTA has been the subject of a number of recent research reports. Analysts at Maxim Group initiated coverage on shares of Momenta Pharmaceuticals in a research note on Thursday, June 5th. They set a “buy” rating and a $17.00 price target on the stock. Analysts at Goldman Sachs initiated coverage on shares of Momenta Pharmaceuticals in a research note on Monday, June 2nd. They set a “buy” rating and a $19.00 price target on the stock. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $19.20.

Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.